National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2020 (No. 10) (PB 112 of 2020) (Cth)

PB 112 of 2020

National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2020
(No. 10)

National Health Act 1953

___________________________________________________________________________

I, THEA CONNOLLY, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Instrument under subsection 84AAA(2) of the National Health Act 1953.

Dated    26^th November 2020

THEA CONNOLLY

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

___________________________________________________________________________

1. Name of Instrument

(1)This Instrument is the National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2020 (No. 10).

(2)This Instrument may also be cited as PB 112 of 2020.

1. Commencement

This Instrument commences on 1 December 2020.

1. Amendment of National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015)

Schedule 1 amends the National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015).

Schedule 1       Amendments

1. Schedule 1, entry for Mesalazine in the form Sachet containing prolonged release granules, 1 g per sachet

omit from the column headed “Maximum quantity or number of units”: 120   substitute: 100

1. Schedule 1, after entry for Norethisterone with ethinylestradiol in the form Pack containing 21 tablets 1 mg‑35 micrograms and 7 inert tablets

insert:

Pack containing 21 tablets 1 mg-35 micrograms and 7 inert tablets USP 20 4 2

1. Schedule 1, entry for Rivaroxaban

insert as first entry:

Tablet 2.5 mg 20 60 5

1. Schedule 1, entry for Venetoclax

substitute:

Venetoclax	Tablet 100 mg	20	120	4
20	120	5